Sativex as an add-on treatment of moderate to severe spasticity in multiple sclerosis (discontinued)
 
Status Discontinued
Process MTA
Referral date 01 May 2002
Topic area
  • Central nervous system
  • Therapeutic procedures

Provisional Schedule

1st appraisal committee meeting: 25 August 2011
2nd appraisal committee meeting: TBC

Project Team

Communications manager: Paul Cooney
Executive Lead: Gillian Leng
Project manager: Kate Moore
Technical Lead: Jennifer Priaulx

Timeline

Key events during the development of the guidance:

Date Update
14 July 2003 As it is unlikely that drobinol (Solvay Healthcare Ltd) will have been granted a UK marketing authorisation in time for it to be considered at the first Appraisal Committee Meeting on 20 January 2004, NICE has suspended the appraisal of drobinal until the licence is granted. The appraisal of CBME (GW Pharmaceuticals Plc) will continue along the existing timeline.
10 November 2003 This appraisal has now been halted following confirmation received by the Institute from GW Pharmaceuticals plc that its product (CBME) has not yet been granted marketing approval. The appraisal will recommence once marketing approval has been granted. At that time, consultees and commentators will be advised of updated timelines for the appraisal.
9 December 2010 NICE is considering the next steps for this technology appraisal. More information will be available in due course.
4 May 2011

The National Institute for Health and Clinical Excellence (NICE) have been commissioned to carry out a technology appraisal of sativex as an add-on treatment of moderate to severe spasticity in multiple sclerosis.

Following the recent draft scope consultation, further discussions with the Department of Health and noting the possible overlap between the Technology Appraisal and the potential review of Clinical Guideline No. 8 ‘Management of multiple sclerosis in primary and secondary care’, it has been decided that the Technology Appraisal will be suspended until the outcome of the review decision process for the Clinical Guideline is known.

Please see http://guidance.nice.org.uk/CG8 for more information regarding the Clinical Guideline No. 8 ‘Management of multiple sclerosis in primary and secondary care’ and the review decision date.

27 October 2011

Following on from the email of 1 April 2011, I am writing to inform you that it has now been decided that a review of Clinical Guideline No. 8 'Management of multiple sclerosis in primary and secondary care' will go ahead and that advice on sativex will be included in the scope of the guideline.

Sativex has therefore been removed from the NICE technology appraisal work programme.

For more information, please see the review decision for Clinical Guideline No. 8 'Management of multiple sclerosis in primary and secondary care'.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance